MTHFR 677 C>T genotype and adverse outcomes in treatment of childhood ALL: is the jury in?
Goyal
Rakesh K
RK
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213-2583, USA. rakesh.goyal@chp.edu
D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2) / Q000235:genetics* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D003596:Cytosine / Q000378:metabolism; D005838:Genotype; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000401:mortality; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D003596:Cytosine; D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2); D008727:Methotrexate